Medical health wearables technology company EnLiSense CCM has obtained funding from the Crohn’s & Colitis Foundation’s IBD Ventures programme for the development of its IBD AWARE product.

IBD AWARE is a real-time inflammation sweat sensor, which targets key biomarkers linked with inflammatory bowel disease (IBD). It is designed to track and monitor IBD activity in patients.

Andres Hurtado-Lorenzo, Crohn’s & Colitis Foundation Translational Research & IBD Ventures vice-president, said: “We are very enthusiastic about supporting EnLiSense clinical studies to further validate their groundbreaking sweat biosensor, following our initial academic investment in this technology via the Foundation’s Novel Technologies Initiative.”

The wearable device samples nano-litres of passive sweat. It also continuously measures and reports biomarkers including Calprotectin, C-Reactive protein, interleukin-6, interleukin-1 beta, tumour necrosis factor-alpha and cortisol.

EnLiSense will use the funds for further clinical studies to support product development and validation.

The trials are expected to accelerate the development of a critical diagnostic tool, which can facilitate research and development to enable personalised treatment and therapies for IBD patients.

EnLiSense CCM CEO Dr Sriram Muthukumar said: “IBD AWARE will provide patients and their clinicians with the real-time, actionable data they need to further the quality of life outcomes.

“IBD AWARE biomarkers would be able to identify those individuals at risk for the disease and be disease-specific; would be able to detect disease activity and monitor the effect of treatment and would have a prognostic value towards relapse or recurrence.”